Prophylaxis and continuous infusion for hemophilia: can we afford it?
Little is known about the ideal factor regimen for hemophiliacs nor how treatment should be administered. A prospective multicenter study evaluated different dosage regimens and defined orthopedic outcomes, based on factor consumption and a comparison of prophylaxis with on-demand therapy. Prophylaxis led to better outcomes, whether joints were initially normal or previously affected. Factor use was substantially more costly if prophylaxis was used, but a major reduction could be achieved if continuous infusion were feasible.
Aledort
L M
LM
Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Bohn
R L
RL
D003362:Cost-Benefit Analysis; D005169:Factor VIII / Q000008:administration & dosage*; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007260:Infusion Pumps / Q000191:economics*; D007592:Joint Diseases / Q000209:etiology / Q000517:prevention & control
D005169:Factor VIII